West Pharmaceutical Services' stock surged 6.02% in pre-market trading on Thursday, following the release of its second-quarter 2026 financial results and an upward revision to its full-year outlook.

The company reported adjusted earnings per share of $2.37 for the quarter, significantly surpassing the analyst consensus estimate of $2.08. Net sales reached $872.3 million, also beating expectations of $838.6 million. The strong performance was attributed to robust demand for components used in injectable drugs, including treatments for diabetes and obesity such as GLP-1 medications.

In response to the quarterly outperformance, West Pharmaceutical raised its full-year 2026 guidance. The company now expects adjusted earnings per share in the range of $8.85 to $9.05, up from its previous forecast of $8.40 to $8.75. Similarly, it increased its net sales projection to between $3.35 billion and $3.38 billion. The raised outlook reflects continued strength in its High-Value Product components and biologics segments, driving investor optimism.